Oric Pharmaceuticals, Inc.
Oric Pharmaceuticals, Inc. (ORIC): 12 pipeline candidates · ~25 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
25.3 months
D/E 0.05 · 2% dilution
Lead: Phase 1/Phase 2
12 candidates
N/A
0 buys · 3 sells (180d)
A transparent, data-derived signal for Oric Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$856.1M
Cash
$56.9M
Quarterly Burn
$32.4M
Runway
25.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| abiraterone acetate 250 mg or | Phase 1 |
| apalutamide 60 mg or | Phase 1 |
| chemotherapy | Phase 1/Phase 2 |
| enozertinib | Phase 1 |
| enzalutamide 40 mg capsules or 40 mg and | Phase 1 |
| oric-114 | Phase 1/Phase 2 |
| oric-114 dose 1 + amivantamab | Phase 1/Phase 2 |
| oric-114 dose 2 + amivantamab | Phase 1/Phase 2 |
| oric-114 dose 3 + amivantamab | Phase 1/Phase 2 |
| oric-533 | Phase 1 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
176
Total value held
$1.12B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 7,374,014 | $93.4M |
| blackrock, inc. | 5,984,552 | $75.8M |
| viking global investors lp | 5,824,533 | $73.8M |
| alkeon capital management llc | 4,504,096 | $57.1M |
| state street corp | 3,702,196 | $46.9M |
| vivo capital, llc | 3,697,572 | $46.8M |
| column group llc | 3,540,777 | $44.9M |
| siren, l.l.c. | 2,998,192 | $38.0M |
| orbimed advisors llc | 2,693,929 | $34.1M |
| woodline partners lp | 2,495,030 | $31.6M |
Showing top 10 of 176 institutional holders of Oric Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Oric Pharmaceuticals, Inc.'s pipeline?
Oric Pharmaceuticals, Inc. (ORIC) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Oric Pharmaceuticals, Inc.'s lead drug candidate?
Oric Pharmaceuticals, Inc.'s most advanced tracked candidate is abiraterone acetate 250 mg or (Phase 1) for Metastatic Prostate Cancer.
What is Oric Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Oric Pharmaceuticals, Inc. has approximately 25.3 months of cash runway.
What is Oric Pharmaceuticals, Inc.'s market capitalization?
Oric Pharmaceuticals, Inc.'s market capitalization is approximately $856.1M.
Who is the CEO of Oric Pharmaceuticals, Inc.?
Dr. Jacob M. Chacko M.B.A., M.D. is the chief executive officer of Oric Pharmaceuticals, Inc. (ORIC).
Get the full picture on Oric Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.